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Analysis the Efficiency and Productivity of Indonesian
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Faculty of Economics and Business, University of Indonesia
As one of the biggest medicines market in the South East Asia, the pharmaceutical industry in
Indonesia has a huge potential market. However, the majority supply of raw materials has been imported. Besides, regulations of the Health Ministry and the Trade Ministry have still hampered most
players in Indonesia pharmaceutical industry. Therefore, this study used Data Envelopment Analysis
(DEA) models to analyze efficiency and productivity change in the Indonesian pharmaceutical industry between 2006 and 2011, listed in the Indonesia Stock Exchange and also supported by applying
efficiency financial ratio. This study finds that the decision for the most relatively efficient company
is different using DEA compared to efficiency financial ratios, yet DEA has better measurement of
efficiency. It is proven by one of State-owned Enterprises has been evaluated underperformed by the
financial ratio analysis, unexpectedly is efficient using the DEA approach. This study has also proposed and tested a hypothesis on the average efficiency to check if the domestic and foreign pharmaceutical companies differ in their efficiency but the result implies that there is no significant statistical
difference among them. This study indicates that firms having dominant contribution in selling overthe-counter medicines are more efficient than selling ethical medicines. Lastly, technological change
contribution has more influence to productivity change instead of pure technical efficiency change in
Indonesia pharmaceutical companies.
Keywords: efficiency, productivity, pharmaceutical companies, Data Envelopment Analysis (DEA),
financial ratio

Introduction
Indonesia is one of the biggest potential
markets for pharmaceutical products in the
South East Asian region. Indonesia accounts
for 37% out of the 650 million populations living in the region1. Most of the market share for
pharmaceutical products, up to 70%, is still
held by local pharmaceutical companies with
a total value of around USD2.4 billion2. Profit
growth opportunities are also promising due to

the population size and the rising annual population growth. However, these growth opportunities may be offset by various challenges.
Indonesia imports more than 95% of raw
materials from India, China and Europe3. This
situation creates vulnerability to the Indonesian
pharmaceutical industry, since the cost of raw
materials becomes highly dependent to the currency value of IDR compared to the currency of
the supplier’s country. Other challenges come
from local regulations considered as constrain-
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ing to foreign pharmaceutical players under
the International Pharmaceutical Manufacturers Group4, especially the Ministry of Health
Regulation (Permenkes) No.1010/2008 concerning Medicine Registration. The regulation
implies that foreign pharmaceutical companies
without local manufacturing plant in Indonesia
may not import pharmaceutical products to Indonesia. On the other hand, 95% raw materials
for Indonesian pharmaceutical industry are still
imported. Moreover, foreign owned companies
usually import their raw materials from their
home country and then formulated the final
product in the host country (Saranga and Phani,
2008). The regulation was further strengthened
by revisions of the definition of pharmaceutical
industry in the Decree of Health Minister (SK
Menkes) No 245/1990 which stated that pharmaceutical companies operating in Indonesia at
minimum must own packaging facilities located in Indonesia, reducing the requirement from
owning a production facility to only a packaging facility. Other regulation comes from the
Ministry of Trade Regulation (Permendag)
No.45/2009 regulating Importer Identifying
number and limitation of foreign ownership
up to 75% stated in the regulation of Negative
Investment List. These regulations become a
disincentive for foreign investors to invest their
funds and the development of foreign owned
pharmaceutical company in Indonesia.
Despite pharmaceutical industry in Indonesia facing many challages, in fact its market share is still very attractive and promising.
Thus, to improve competitiveness in order to
expand market share, pharmaceutical companies are required to be more productive and efficient in running the company operations.
Based on the problems stated above, this
paper aims to investigate the efficiency and
productivity of publicly owned pharmaceutical company in Indonesia. Several researchers have studied efficiency and productivity of
pharmaceutical industries, most of which are
conducted in Europe, Japan and India (Fare et
al., 1995; Gonzales and Gascon, 2004; Danzon
et al., 2005; Hashimoto et al., 2008; Saranga
and Phani, 2008; Mazumdar and Rajeev, 2009;
4

and Pannu et al., 2011). Conversely, the efficiency and productivity of pharmaceutical industries in the South East Asian region -such
as Indonesia- are rarely studied. Therefore,
this study tries to expand the body of research
conducted previously in Europe, Japan and India, by conducting the study in Indonesia. This
study also compares relative efficiency measured with DEA with efficiency calculated using efficiency financial ratios. Furthermore, this
study tests whether difference of means exists
between the efficiencies of local and foreign
owned pharmaceutical companies, as well as
identifying changes in productivities and the
dominant determining factors.

Review of Related Studies
Most of the previous studies regarding the
pharmaceutical industries are motivated by
various constraining regulations in relation
of the pharmaceutical industries themselves
(Gombola and Ketz, 1983; Lothgren and Tambour, 1998; Barnum et.al., 2001; Gonzales and
Gascon, 2004; Saranga and Phani, 2008; Mazumdar and Rajeev, 2009; Xu and Wang, 2009;
Lin et al, 2011; Pannu et al., 2011; Maricica
and Georgeta, 2012; Patel and Pande, 2012;
Delen, Kuzey and Uyar, 2013). Saranga and
Phani (2008) discovered that positive relations
exist between internal efficiency and corporate
growth in the dynamic environment of Indian
pharmaceutical industries. The dynamic environment was influenced by the changes in regulation regarding foreign ownership of pharmaceutical companies from a maximum of 40% to
74% and also of Intellectual Property Protection
(IPI). This finding is further strengthened by the
study of Pannu et al. (2011) which discovered
that a pharmaceutical corporation with higher
efficiency enjoys higher compounded average
growth rate (CAGR) of their sales.
Mazumdar and Rajeev (2009) studied factors influencing the efficiency of pharmaceutical corporations, such as corporate size, existence of R&D unit, target market segment and
existing products. The study concludes that
large pharmaceutical corporation has greater

http://www.businessreview.co.id/bisnis-investasi
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efficiency due to the profits from invested technological innovations. They also find that the
sector experienced rapid technological progress
in recent years. Leading to a rise in the inefficiency for this sector, the most firms have failed
to appropriate the benefits of the technological
change. Their other finding mentioned that in
the context of the Indian pharmaceutical industry, an extremely effective strategy for firms’
benefit from efficiency and technological gains
can be implemented by merging vertically with
downstream raw material.
Conversely, the existence of R&D unit was
found to have no significant effect to corporate efficiency. However, firms that invested in
R&D profited from technological innovation.
This suggests that the few frontier firms profited most from their R&D related outlays, but
this investment enlarged the distance between
the inefficient and efficient firms. Large firms
that invested more in R&D have profited from
technological growth. Thus, firms can expand
their production possibilities, enabling themselves to realize higher margins by increasing
the scale of operation backed by sufficient R&D
activity. This finding supports earlier study by
Hashimoto and Hanaeda (2008) in Japanese
pharmaceutical companies which assessed that
the existence of R&D unit is meant to increase
company value more rather than increase corporate efficiency. The firms have continued to
increase R&D expenditure every year although
R&D efficiency has not improved. Possibly,
firms might have found another meaning of
R&D expense than R&D itself. However, it is
certain that there has been the shortage of firms’
R&D efficiency evaluation.
Alternatively, Pannu et al. (2011) proved
that the existence of R&D unit can increase efficiency. Pannu found that the efficiency and
productivity change leaders and laggards over
10 year period. Pannu also proved that the efficiency of local companies is lower than the
average efficiency of MNCs between 1998 and
2007. However, there is no difference between
multinational and local companies in the average productivity change between 1998 and
2007. According to this paper, close to 70% of
local companies have average efficiency scores
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less than the worst efficiency score among
MNCs. This basically shows that the input–output balance among multinational companies is
better than that of Indian companies. They also
noticed that the inefficient companies are lower
than the CAGR of efficient companies. Also,
they have analysed the effect of firm size and
found that compared to small and micro firms,
larger firms posted a higher CAGR, efficiency
and relative efficiency. However, smaller firms
led the larger firms in productivity change and
technical change. Their finding shows that,
though it is declining for both the groups after
2004 for the ten year period, efficiency of innovative firms was higher than non-innovative
firms on a year to year basis. While neither
global nor domestic market orientation influences efficiency, local regulation significantly
influences them. Finally, corporations which
produce bulk of medicines and formulation
medicine were found to have greater efficiency
so that integrated production strategy would
lead to greater efficiency in pharmaceutical
companies. This finding supports earlier finding by Saranga and Phani (2008). They have
seen that the internal efficiency ratings are not
dictated by size of a company. Excepting for a
few instances where companies which were in
the mode of expansion, the methodology establish the fact that there is a direct relationship
between internal efficiencies and higher growth
rates. Those instances may not have achieved
full efficiencies. Internal efficiencies have been
established by the local companies in bulk
medicine and formulation businesses, which
have helped them to arise so far, will also play
a principle role in grabbing the new opportunities of product patent era, to survive and arise
in future.
Research on productivity of pharmaceutical companies was pioneered by Fare et al.
(1995) by studying pharmaceutical companies
in Sweden. Fare et al. (1995) classified changes
in total productivity factors into technical efficiency change, technological change and quality change. The study discovered that differences exist between productivity measures when
quality was entered as an attribute. On average,
pharmaceutical companies experience an in-
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crease on productivity, technological changes
and efficiency changes when quality was entered in the equation.
Proposing a modification of the DEA network model by Fare and Grosskopf (1996),
Lothgren and Tambour (1998) allow a representation of both production and consumption
technologies in a unified framework. The inputs
directed to customer activities, together with
the production quality attributes is presumed to
give customer satisfaction, here represented by
assessments of quality from barometer surveys
of customer satisfaction. The results obtained
from the network model and non-network
productivity model are similar in some acknowledgement. In both models the estimated
productivity change is positive. However, the
network model indicates a lower estimated productivity progress than the non-network model.
The progress in productivity is indicated by
both the efficiency and technical change components in the Malmquist index decomposition.
The accounts of technical change component
for most of the progress, although this is more
clear in the non-network model than in the network model. However, there are some differences regarding which pharmacies are experiencing progress and regress in productivity in
the different models. Taking customer satisfaction into account, the network model proposed
by Lothgren and Tambour (1991) was constructed with the purpose to estimate efficiency
and productivity for the sample of pharmacies.
However, it should be noted that the proposed
model can be applied to arbitrary industries as
long as the data include information on customer satisfaction, production quality attributes
and firm-specific input allocation to customer
and production oriented activities. It means that
the proposed model is not limited to the specific
pharmacy application.
Gonzales and Gascon (2004) examined the
productivity of pharmaceutical laboratories after the deficit cero policy in Spain which caused
many pharmaceutical companies to reduce their
profit margin. They discovered that pure technical efficiency change and scale efficiency
change are the two dominant factors influencing productivity growth. Similar finding was

https://scholarhub.ui.ac.id/icmr/vol6/iss2/4
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obtained in the Indian pharmaceutical industry
under the amended Medicines and Cosmetic
Act (Mazumdar and Rajeev, 2009). It also
found that technological innovation applied by
the Indian companies does not increase productivity growth.
Focusing the study on performance evaluation of pharmacy retail stores, Patel and Pande
(2012) found that retail stores are operating at
average efficiency levels and there is a lot of
improvements scope. The stores performing
inefficiently need to focus upon their footfalls,
sales, operating expenses and store size. Experiencing increasing returns to scale is a well
planned strategy that must be practiced by the
inefficient stores. The most suitable strategy for
the stores experiencing decreasing returns to
scale, however, is to lower down their scale of
operations. Patel and Pande conclude that the
study provides a framework for performance
evaluation of pharmacy retail stores along with
identification of efficient drivers of performance
Suggesting DEA model in hospital pharmacies, Barnum et al. (2001) developed a study
of integrated procedures that can both mitigate
the problems and take advantage of the frequent and detailed information now available.
First, they suggest a set of compatible and
comprehensive measure of distributional and
clinical output, some of which are only available because of the computerized information
system. As a result, all of the key distributional
and clinical outputs are covered. Second, they
suggest DEA models that can separately summarize the efficiency of the pharmacies’ clinical
and distributional activities; with a third model
that appraises the pharmacies’ comprehensive
efficiency as a whole. Third, it suggests a methodology for developing statistical control charts
through the use of statistical PDA models, so
pharmacy managers can quickly and accurately
differentiate when conditions are indeed out of
control and when the reports merely reflect random variations. They believe that the collective
use of these suggestions could provide significant assistance to hospital pharmacies seeking
to increase and maintain their efficiency.
In the proposed prediction scheme, the efficiency of corporation is obtained through DEA.
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In that study, Xu and Wang (2009) explained on
their paper. They propose a prediction approach
using efficiency of corporation as a predictor.
The efficiency and some selected financial ratios are then used as predictors in prediction
methods. The numerical results of application
to corporations in Shanghai stock exchange
validate the efficacy of the proposed prediction
scheme.
Lin, Liang and Chen (2011) study a set of
financial features that includes 21 commonly
used financial ratios that are expected to achieve
a more accurate prediction of corporate financial distress than a model based exclusively on
scholars’ survey results from experts. In a similar case, identifying and using a large and feature rich dataset was studied by Delen, Kuzey
and Uyar (2013). After a long search they identified FINNET, a company providing variety of
financial data, software, and Web-based analysis tools to their members. They covered the
time period of 2005 to 2011 for the final dataset
of financial ratios. They find that profitability
ratios can predict financial distress well. These
ratios indicate the potential ability of a company in case of controlling costs and expenses.
The more successfully the firm can control its
costs and expenses, and by improving its performance (represented as ROE and ROA), the
higher these ratios. Further, the Leverage and
Debt Ratios are also found to be able to predict
financial distress as well.
Either classic or modern bankruptcy prediction model, are principally based on financial
ratios. The study was done by Maricica and
Georgeta (2012). They argue about the importance of the information quality provided by financial ratios in bankruptcy prediction because
it impacts on the accuracy of the bankruptcy
prediction. Surely this can be used to measure
how efficiently a resource that can be used by
the company, which in this study is the financial
resources.

Methodology
Efficiency measures were calculated using
non parametric approach with Data Envelopment Analysis (DEA) method introduced by
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Charnes et al. (1978). Efficiency measures using DEA involves a minimum of one output
and three inputs (Pannu et al., 2011), in which
sales is the only output entered while the inputs entered are 1) Cost of Material, 2) Cost of
Manpower, and 3) Capital Cost. The last input,
capital cost, was calculated from the total cost
of sales and production minus the cost of raw
material and worker’s compensation.
In calculating efficiency using panel data,
efficiency measurement was conducted using
DEA-like linear programs while the Malmquist
Total Factor Productivity (TFP) Index was
employed to measure productivity change as
well as to decompose productivity change into
technological change and technical efficiency
change.
Caves et al. (1982) showed that productivity
changes can be assessed by Malmquist indices,
defined in terms of ratios of distance functions.
Following Fare et al. (1995) an input-based
Malmquist productivity index for the P-Node
can be defined (and decomposed) as:
1)

2)
where
is the distance function
which measures the maximum proportional
change in outputs required to make (xt+1, yt+1)
feasible in relation to the technology at time t.
Productivity improvement is signaled by a
Malmquist index less than one and a negative
change in productivity is signaled by an index
greater than one. The term outside the brackets,
Ei, measures change in efficiency and can be interpreted as a ``catching up'' (to the production
frontier) effect. The TCi term measures change
in technology in terms of shifts in the production frontier.
The Malmquist Productivity change index was
specified based on Fare et al. (1994) as follows:

2.1)
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The value (xt+1, yt+1) is the value of productivity relative to (xt, yt). The value of productivity greater than one indicates the existence
of positive TFP growth from period t to period
t+1. This index was derived from four linear
programming functions, as follows:

2.2)
Function 2.2 above is the function of Variable Return to Scale (VRS). VRS is the assumptions used on the basis that no company in the
pharmaceutical industry is currently operating
at optimal level due to imperfect competition,
one of which is caused by the government regulation. While the other three linear programming functions are:

2.3)

2.4)

2.5)
Whereas θ is a scale, λ is the vector Nx1 at
the condition of constant return to scale, yi is
the output and xi is the input, Y is the matrix
output for all companies in the industry, X is the
matrix input for all companies in the industry
while N1λ = 1 is the convexity constraint ensuring that an inefficient company is selected as
benchmark for similar sized companies.

https://scholarhub.ui.ac.id/icmr/vol6/iss2/4
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Additionally, other than efficiency measures
using DEA, this study also used financial ratios
represented by cash efficiency ratio (cash ratio, quick ratio and current ratio) and asset efficiency ratio (Inventory turnover, net working
capital turnover, fixed asset turn over and total
asset turnover).
Ross (2008) explained the formula for all
the financial ratios in this study. Xu and Wang
(2009) using quick ratio, cash ratio, inventory
turnover and total asset turnover as the predictors in prediction methods for financial failure
prediction. Maricia and Georgeta (2012) using current ratio and quick ratio to analyze the
business failure risk in their study. Delen et. al.
(2013) using Liquidity ratios (cash ratio, quick
ratio, current ratio) and turnover ratios (inventory turnover, net working capital turnover,
fixed asset turnover and total asset turnover)
for measuring firm performance with a decision
tree approach. The ability of a company to pay
a short-term debt can be evaluated by liquidity
ratios, whereas long-term solvency ratios used
to investigate the risk level of an investment in
the firm could be for creditors. Turnover ratios
used to measure the success level of the company, so that it generates revenues through utilizing assets, collecting receivables, and selling its
inventories. According to the previous related
studies, this paper used the following efficiency
ratios:
Current ratio =

3)

Quick ratio =

4)

Inventory turnover =

5)

Net working capital turnover =

6)

Net working capital = current assets - current liabilities

7)

Fixed asset turnover =

8)

Total asset turnover =

9)

Cash Ratio =

10)
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Figure 1. Research framework
Table 1. Descriptive Statistics Analysis (in USD*)
Description
Sales
Cost of Material
Cost of Manpower
Cost of Capital

Mean
275,485
183,357
21,417
41,390

Std Dev
339,723
243,417
26,031
61,706

Minimum
6,731
2,315
645
1,918

Maximum
1,196,093
1,031,575
116,609
266,579

Lower Quartile Middle Quartile Upper Quartile
39,387
104,329
382,000
18,796
81,542
250,116
3,853
10,686
31,988
4,741
18,051
39,087

Source: Output Stata 11 (Processed)
*Exchange rate: Rp 9,113/USD published by Bank Central of Indonesia per December 30th, 2011

Data and Design
This study is an explanatory analysis which
aims to explain the value of relative efficiency
and productivity changes produced from three
inputs to a single output. The data employed
in this study are balanced panel data covering
the entire pharmaceutical companies listed in
the Indonesian Stock Exchange period 2006 –
2011. During that period, there are twelve pharmaceutical company listed with various type of
ownership. However, only eleven companies
are included in the sample due to one company
operates mainly in the supply of medical equipments and also incomplete data. All data was
obtained through Thomson Reuters Knowledge
and DataStream. Research framework employed in the study is shown in Figure 1.
Empirical Result
Statistic Descriptive
The publicly listed pharmaceutical companies included as sample for this study can
be categorized based on ownership into three
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groups: 1) two state owned/majority companies, 2) three privately owned domestic companies and 3) six foreign owned companies. Inputs and output values for each companies used
in the DEA calculation are shown in Table 1.
Descriptive statistics showed that the largest expenditure for Indonesian pharmaceutical
companies is the cost of materials with an average of USD183,357.18 covering raw materials,
manufacturing and warehousing. The second
is the cost of capital with an average of USD
41,390 covering fixed assets expenditures, machinery installation and intangible assets. While
the cost of manpower is the least expenditure
allocated with an average of USD21,417.46
covering both direct and indirect labor costs.
Thus, the proportion between the total cost of
material, cost of capital and cost of manpower
are 9:2:1 respectively. The size of expenditures
of material is mostly due to the majority of
raw materials for Indonesian pharmaceuticals
which must be imported from various countries
such as India, China and European countries.
Thus the material cost is influenced heavily by
the low value of Indonesian currency relative to
the country of the suppliers.

7
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Table 2. Average Value of the Pharmaceutical Company Efficiency during 2006 – 2011
Period Using DEA
Company Name
Darya-Varia Laboratoria Tbk
Enseval Putra Megatrading Tbk
Indofarma Tbk
Kimia Farma (Perseroan) Tbk
Kalbe Farma Tbk
Merck Tbk
Pyridam Farma Tbk
Schering Plough Indonesia Tbk
Millennium Pharmacon International Tbk
Taisho Pharmaceutical Indonesia Tbk
Tempo Scan Pasific Tbk

2006
0.096
0.219
1
0.786
1
0.610
0.943
0.727
0.818
0.909
1

2007
0.091
0.182
1
0.571
1
0.545
0.636
0.727
0.818
0.909
1

Efficiency (VRS)
2008
2009
0.092
0.104
1
0.182
1
0.333
0.571
0.414
0.455
0.537
0.699
0.565
0.651
1
1
0.727
0.971
1
0.909
0.909
1
1

2010
0.091
0.182
1
0.571
0.455
0.545
0.636
0.727
0.818
0.909
1

2011
0.108
0.226
1
0.583
0.455
0.592
1
0.938
1
0.909
1

Source: Output Deap (Processed)

Companies Efficiency
Table 2 illustrates the relative efficiency value of Pharmaceutical Companies listed in the
Indonesian Stock Exchange during the 20062011 periods using the DEA calculation. Efficiency value of 1 indicated the most efficient
corporation.
Efficiency measurement using DEA showed
that on average, the five most efficient companies are Tempo Scan Pasific Tbk with efficiency
value of 1,00, followed by Taisho Pharmaceutical Indonesia Tbk (0.909), Millennium Pharmacon International Tbk (0.904), Indofarma
Tbk (0.889) and Pyridam Farma Tbk (0.811).
Conversely, the two least efficient pharmaceuticals companies in Indonesia are Darya-Varia
Laboratoria Tbk (0.097) and Enseval Putra
Megatrading Tbk (0.332). Based on the ownership, three out of five most efficient companies
are foreign owned companies, one is a privately
owned domestic company and one is a state
owned/majority company.
Tempo Scan Pasific Tbk and Taisho Pharmaceutical Indonesia Tbk as the two top most
efficient companies have different ownership
structure, with Tempo Scan Pasific Tbk as domestic privately owned and Taisho Pharmaceutical Indonesia Tbk as foreign owned company.
However, both are producers focusing on making and selling Over the Counter (OTC) Medications.
Tempo Scan Pasific Tbk sales of OTC medications contribute to up to 90% of total sales,
5
6

while prescription only contributes 10% (Ethical) of total sales. Based on the 2011 data, the
market share of Tempo Scan Pasific Tbk in the
OTC segment reached up to 45.1% of total
OTC sales in Indonesia5. Similar focus was also
adopted by Taisho Pharmaceutical Indonesia
Tbk whose OTC sales contributed up to 78%
of total sales6. Good target market and strong
focus on OTC sales has made this company to
have the best efficiency in the Indonesia pharmaceutical industry. Thus, it can be said that
stronger focus on OTC medicines might increase efficiency of Pharmaceutical companies
in Indonesia.
This factor may be attributed to the greater
size of annual total sales for OTC medicines as
well as the tendency of Indonesia consumer to
self prescribes their medication. Based on the
data by the Indonesian Central Biro of Statistics
(BPS) in 2010, majority people in Indonesia
(68.71%) prefer to self medicate themselves, by
choosing their medicine without doctor’s prescriptions. Additionally, 27.58% of Indonesians
prefer self medication by using factory made
traditional medicine recognized and registered
by the Indonesian Health Ministry. This means,
only 3.71% Indonesian prefer to doctor’s prescriptions when choosing medications and
the rest prefers using self prescribed over the
counter medicine sold openly in retail outlets.
Such Indonesian demographic characteristics
become the main reason Tempo Scan Pasific
Tbk and Taisho Pharmaceutical Indonesia Tbk
focusing on the production and sales of OTC

http://www.indonesiafinance today.com
http://www.indonesiafinancetoday.com/read/24520
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Table 3. Average Value of the Pharmaceutical Company Efficiency during 2006 – 2011
Period Using Efficiency Financial Ratios (in times)
Company Name
Darya-Varia Laboratoria Tbk
Enseval Putra Megatrading Tbk
Indofarma Tbk
Kimia Farma (Perseroan) Tbk
Kalbe Farma Tbk
Merck Tbk
Pyridam Farma Tbk
Schering Plough Indonesia Tbk
Millennium Pharmacon International Tbk
Taisho Pharmaceutical Indonesia Tbk
Tempo Scan Pasific Tbk
Industry Average for Indonesian
Pharmaceutical Industry

Average Cash Efficiency
Cash
Quick Current
Ratio
Ratio
Ratio
1.70
3.60
4.30
0.25
1.11
1.92
0.35
1.10
1.46
0.49
1.43
2.25
1.42
2.73
4.06
2.46
4.59
6.36
0.13
1.12
2.03
0.09
0.63
1.32
0.13
0.85
1.41
1.87
3.67
4.31
1.89
2.81
3.70
0.98

2.15

3.01

Inventory
Turnover
3.057
7.050
5.127
5.612
2.900
3.399
2.187
1.596
7.966
4.154
4.623
4.330

Average Asset Efficiency
NWC
Total Asset
Turnover
Turnover
1.813
1.016
7.104
2.883
5.671
1.390
5.128
1.833
2.561
1.372
2.573
1.702
6.336
1.144
-8.515
1.161
11.940
3.194
2.145
1.126
2.503
1.270
3.570

1.640

Fixed Asset
Turnover
4.883
23.397
11.458
6.709
6.069
11.977
2.074
6.340
101.071
4.724
5.739
16.770

Source: Thomson-Reuters Knowledege (Processed)

medicines enjoy greater efficiency relative to
other pharmaceutical companies with less focus
on OTC medicine.
However, such demographic characteristic
may come as a shock since according to the
2010 Census by the Indonesian Central Biro of
Statistics; up to 31,023,400 people (16.56%)
of the total population are considered below
the poverty line. While the Indonesian government through the Ministry of Health provides
free health care and medical treatment in form
of the Health Insurance (ASKES), the Public
Health Insurance (JAMKESMAS) and the Local Public Health Insurance (JAMKESDA) for
40% of the poorest Indonesians to enable their
access to better health care (Holloway, 2011).
Ideally, with the lower portion of poor people
and better access to health care, people would
use that opportunity to go to health care facility
and consume medication as prescribed by the
doctor instead of doing self medication.
Therefore, there are two possible explanations on why Indonesians still prefers self-medication than doctor’s prescriptions. First, government health care aid might not reach the real
segment, thus many of the poorer population
can not access health care aids given in medical
facilities due to their financial limitation. This
condition forces them to consume OTC medication sold in retail outlets rather than prescribed
medicines. Second, the mind set of many Indonesians may really prefer OTC medicies, thus
avoiding or ignoring the doctor’s prescriptions
106
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when they are ill.
On the other hand, even though both Tempo
Scan Pasific Tbk and Taisho Pharmaceutical
Indonesia Tbk have the greatest relative efficiency based on DEA calculation, their financial efficiency ratios are not better than those
with lesser relative efficiency. Tempo Scan Pasific Tbk and Taisho Pharmaceutical Indonesia
Tbk has cash efficiency ratio above the industry
average, while Millennium Pharmacon International Tbk has the lowest cash efficiency ratio
in the idustry (See Table 3). Lower cash efficiency ratio means greater ability of the company to manage their cash and current assets. On
the other hand, Millennium Pharmacon International Tbk has the highest asset efficiency ratio
in the industry, while Tempo Scan Pasific Tbk
and Taisho Pharmaceutical Indonesia Tbk have
below average ratios. Asset efficiency ratio implies that higher ratios means higher efficiency
in utilizing their assets.
Millennium Pharmacon International Tbk
has asset turnover ratio of 101.071, well above
the industry average of 16.77 as shown in Table 3. This is due to the core business of the
company which focuses on the distributions of
pharmaceutical products. As a distributor, Millennium Pharmacon International Tbk does not
need fixed assets as large as the manufacturers
which mass produce pharmaceutical products.
Therefore, the company obtained far greater
fixed asset turnover compared to others in the
industry.
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Differences in the order of the most to the
least efficient companies between DEA and
the efficiency financial ratio may be attributed
to the number of factors entered. In order to
measure efficiency, DEA used multiple inputs
to assess one or more outputs; while financial
ratio can only use one input to assess one output in a given time. This limitation of efficiency
financial ratios to describe the overall company
activities in measuring efficiency may lead to
a bias in measurements (Saranga and Phani,
2008).
One interesting finding is the efficiency of
Indofarma Tbk, which obtain the best relative
efficiency together with Tempo Scan Pasific
Tbk in five out of the six periods employed in
the study. Indofarma Tbk is one pharmaceutical company which per Desember 2011, was
majority owned by the state (80.1%), while
19.3% of the shares was owned by public and
0.6% owned by the employees. This is contrary
to the well known fact that this company has
low profitability. There are several possible
explanations to this finding. First, that is efficiency measurement using DEA assumed that
sales, and not profitability to be the output of
pharmaceutical companies. Thus, even though
Indofarma Tbk may have low profitability, this
is not due to low sales volume. As known, Indofarma Tbk as Majority State Owned-company
has greater authorization to distribute pharmaceutical products than foreign owned or domestically owned private companies. As the largest
producer of generic medicines in Indonesia, Indofarma Tbk distributes its production to various government owned service centers in the
capital as well as in the provinces. Even though
the margin for generic medicines has been set
to a minimum by the government, the large volume of sales in generic medicines has kept Indofarma Tbk efficient.
Second, the efficiency gained by Indofarma Tbk may have been obtained due to tangible assets supporting the production capacity.
Historical record showed Indofarma Tbk as
the first pharmaceutical company founded by
the Dutch-Indian colonial government. At that
time, the colonial government invested large
capacity machinery to mass produce medicines,
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thus gave Indofarma Tbk a head start as the
prime supplier of medicine to Indonesians. This
head start in production capacity enabled lower
and more efficient fixed costs for the company
due to process innovation, which is conducting manufacturing process at the lowest possible cost by maximizing the economies of scale
(Belcher and Nail, 2000).
However, when measured using efficiency
financial ratio, Indofarma Tbk has a slightly
lower total asset turnover than Kimia Farma
(Perseroan) Tbk, even though Indofarma Tbk
still has better overall cash and asset efficiency.
Kimia Farma (Perseroan) Tbk is another state
owned/majority pharmaceutical company included in the sample. Even though they are both
state controlled, Kimia Farma (Perseroan) Tbk
has greater total sales due to more vertically
integrated operation while Indofarma Tbk focuses more on the production of generic medicines with lower price per unit. This shows that,
despite larger the sales volume, Indofarma Tbk
has lower ratio of sales to total asset compared
to Kimia Farma (Perseroan) Tbk due the low
cost nature of generic medicines it produces.
During 2009, Indofarma Tbk experiences a
sharp drop in efficiency from 1.00 in 2008 to
only 0.33 in 2009. This drop in efficiency is
due to the increase of raw material price imported mostly from India. The price increased
due to the global financial crisis which led to
the devaluation of Rupiah. The problem thus
compounded due to the inability of Indofarma
Tbk to cross subsidize the production of generic medicines, thus forcing the management to
postpone the import of raw material and reducing the production of least profitable products.
This decision resulted in the decrease of sales
which in turn reduces efficiency. This condition
does not affect Indofarma Tbk alone, but also
influences other pharmaceutical companies,
such as Pyridam Farma Tbk, Kalbe Farma Tbk,
Schering Plough Indonesia Tbk, Kimia Farma
(Perseroan) Tbk and Merck Tbk, as shown in
their lower efficiency during the 2008-2009 periods.
Even though the global financial crisis in
2009 has affected the efficiencies of pharmaceutical companies in Indonesia across the
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board, according to DEA calculation DaryaVaria Laboratoria Tbk and Enseval Putra Megatrading Tbk was shown to be the least efficient
on average, relative to other pharmaceutical
companies operating in Indonesia. Darya-Varia
Laboratoria Tbk is a foreign owned pharmaceutical company which focuses on the prescribed
medicine segment, contributing up to 51% of
their total sales compared to 36% contribution
of consumer health products. This focus on
prescribed medicine is in total opposite to the
strategy of Tempo Scan Pasific Tbk and Taisho
Pharmaceutical Indonesia Tbk which are shown
as the most efficient companies of publicly
listed pharmaceutical companies in Indonesia.
This difference in product and consumer target
may be the cause of differences in efficiency
between the companies.
Not only when calculated using DEA, the
efficiency of Darya-Varia Laboratoria Tbk was
also low when calculated using financial ratios.
On average, Darya-Varia Laboratoria Tbk has
greater cash efficiency ratios (See Table 3),
which means that Darya-Varia Laboratoria Tbk
reserved more current assets to meet its short
term liabilities, which led to less efficient utilization of cash. Conversely, its asset efficiency
ratio was constantly above the industry average, implying that the company’s asset utilization was relatively efficient.
Enseval Putra Megatrading Tbk is a domestic private owned pharmaceutical company. In
contrast to other pharmaceutical companies
which experiences sharp decrease of efficiency
in 2008 due to the global financial crisis. Enseval Putra Megatrading Tbk experienced the
best efficiency relative to other Indonesian pharmaceutical companies, despite having lower efficiency during other periods. The calculation
using DEA was in opposite to the calculation
using financial ratio. On average, the cash efficiency ratio of Enseval Putra Megatrading Tbk
are lower than industry average while on average the asset efficiency ratio was consistently
higher than the industry average. This showed
that according to the financial ratios, Enseval
Putra Megatrading Tbk was efficient in managing its cash and assets.
7

Domestic vs Foreign Efficiency Companies
Based on differences in the efficiency between groups of domestic and foreign owned
pharmaceutical companies, this study tests
the significance of such differences. This idea
stems from the regulations regarding pharmaceutical companies in Indonesia considered to
be constricting to foreign pharmaceutical players united in the International Pharmaceutical
Manufacturers Group7.
Despite the government effort to relax the
regulation regarding foreign owned pharmaceutical companies, existing regulation are still
tought to be strong disincentive for foreign investments in the pharmaceutical industry. Such
disincentive, if true, would constrict the activities of foreign owned pharmaceutical companies proven by differences in the size of investment activities between domestic and foreign
owned pharmaceutical companies.
Based on Table 4, the top three companies
with the largest investment activities are Kalbe
Farma Tbk, Tempo Scan Pasific Tbk and Enseval Putra Megatrading Tbk which were all
domestic owned companies. On the other hand,
two companies with the least investment activities are Millennium Pharmacon International
Tbk and Pyridam Farma Tbk which were both
foreign owned companies. Also, t-test in Table
5 shows there are significant differences in investment activities between domestic against
foreign owned company at confidence level
95%.
Further testing was also conducted to compare the differences between the efficiency of
domestic and foreign owned companies using
independent sample t-test with confidence level
of 95%. Whereas, the hypothesis for this test is:
Ho: There is no difference between the average
efficiency of domestic and foreign-owned
pharmaceutical companies in Indonesia.
Ha: There is a difference between the average
efficiency of domestic and foreign-owned
pharmaceutical companies in Indonesia.
Based on the test result shown in Table 6,
the null hypothesis can not be rejected. This
means that there is no difference between the
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Table 4. Investment Activities of Indonesian Pharmaceutical Companies during 2006 – 2011
Period (in USD*)
Company
Kalbe Farma Tbk
Tempo Scan Pasific Tbk
Enseval Putra Megatrading Tbk
Kimia Farma (Perseroan) Tbk
Darya-Varia Laboratoria Tbk
Taisho Pharmaceutical Indonesia Tbk
Schering Plough Indonesia Tbk
Indofarma Tbk
Pyridam Farma Tbk
Millennium Pharmacon International Tbk
Merck Tbk

2011
69,236,695
19,846,264
17,153,736
5,968,287
3,751,344
1,428,948
1,171,513
378,909
229,123
116,098
-9,811,588

2010
25,472,841
9,327,774
15,213,541
1,462,197
3,491,166
2,422,583
428,618
496,214
299,901
205,531
2,336,772

2009
70,826,292
11,118,622
10,251,070
8,105,125
2,182,377
461,648
627,236
2,074,289
205,201
682,761
1,829,913

2008
20,435,093
3,929,222
5,543,729
2,915,725
1,749,259
1,537,803
446,944
1,113,355
206,408
1,079,008
1,412,488

2007
4,638,538
8,408,318
5,584,769
3,094,700
3,637,551
2,274,333
878,525
811,588
513,113
325,908
868,649

2006
28,543,070
6,555,360
-20,331,943
2,525,623
1,037,529
855,810
1,305,278
20,191
150,664
67,047
549,325

Source: Annual Cash Flow - Reuters Knowledge (2011)
*Selling rate: Rp 9.113/USD published by Bank Central of Indonesia per December 30th, 2011

Table 5. Descriptive Statistics Independent Sample t-test between Indonesian Domestic and
Foreign Owned Pharmaceutical Companies in Investing Activities
Ownership

Obs.

Domestic
Foreign Owned
t-statistics
p-value

30
36

Investment
Mean
24.79
109.63

Variance
17.05
30.51
-24.272
0.0192

Source: Output Stata (Processed)

Table 6. Descriptive Statistics Independent Sample t-test between Indonesian Domestic and
Foreign Owned Pharmaceutical Companies
Ownership
Domestic
Foreign Owned
t-statistics
p-value

Average Efficiency

n
5
6

Mean
0.690733
0.686917

Variance
0.117688
0.126936
-0.022
0.9829

Source: Output Stata (Processed)

average efficiency of domestic and foreignowned pharmaceutical companies in Indonesia.
This result is in contrast to the finding of Pannu
et al. (2009), which stated that partially, foreign- owned companies has lower efficiencies
than domestic-owned companies due to lesser
size of investments. This outcome led to earlier hypothesis that foreign-owned companies
may not be able to achieve optimum economies
of scale due to regulation issues. The current
finding in this study, however, showed that on
average there are no differences between the efficiencies of domestic and foreign-owned pharmaceutical companies in Indonesia.
The absence of differences between the
mean efficiency of domestic and foreign owned
group of companies refute the opinion that ex-

https://scholarhub.ui.ac.id/icmr/vol6/iss2/4
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isting government regulation, such as ownership proportion and importing licence policies,
may constrain the operation of foreign owned
companies disproportionately. Foreign owned
pharmaceutical companies such as Taisho Pharmaceutical Indonesia Tbk, Millennium Pharmacon International Tbk and Pyridam Farma Tbk
can operate efficiently and compete with various domestic companies, both private and state
controlled. This result supports the hypothesis
that market and product selection influences efficiency. Companies which sold more over the
counter medicines has greater efficiency than
companies which sold more prescribed medicines, irrespective of their ownership.
The absence of differences between foreign
and domestic companies does not refute the

109
12

Hanggraeni: Analysis the Efficiency and Productivity of Indonesian Pharmaceut
INDONESIAN CAPITAL MARKET REVIEW • VOL.VI • NO.2

Table 7. Average Efficiency, Technological Change, Efficiency Change and Total Factor
Productivity Change
Year
2006
2007
2008
2009
2010
2011

Output Efficiency
0.737
0.680
0.759
0.616
0.630
0.710

Technological Change
-0.862
0.600
1.429
0.550
0.653

Pure Technical Efficiency Change
-0.908
1.166
0.767
1.041
1.135

Total Factor Productivity Change
-0.766
0.625
1.256
0.572
0.741

Source: Output Deap (Processed)

view that Indonesian pharmaceutical industry
may be considered as a highly regulated industry in comparison to other pharmaceutical
industries in South East Asia. The strict regulation may force foreign owned companies to
abide the regulations by allocating their investments to build manufacturies and purchase
heavy machineries as well as operational licence in Indonesia. The large initial cost may
reduce efficiency across the board and lengthen
the break even point to new entrants, compared
to existing players. On the other hand, the regulation for domestic companies may have been
set more relaxed in a way that the market nearly becomes perfect competition, which enables
players to enter and exit the market freely. This
condition forces existing players to adopt price
penetration strategy to be able to compete and
sell more products. This strategy in turn caused
domestic players to be relatively less efficient
in generating revenues than it should be (Mazumdar dan Rajeev, 2009). Both sides of the
regulation experiences different challenges
which created inefficiencies, thus domestic and
foreign owned pharmaceutical companies in Indonesia exhibit relatively similar level of efficiency regardless of ownership and regulations.
Productivity Changes
It is shown in the second column of Table
6 that the average output efficiency of pharmaceutical companies in Indonesia is 0.737. This
meant that on average pharmaceutical companies in Indonesia can increase their output by
26% without adding any additional input. The
fluctuating average output efficiency between
the 2006 to 2011 period indicates two possible
outcomes. First, an outward shift may occur
across the board when the average efficiency
110
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increases, which meant an increase of internal efficiency from each decision making unit
(DMU) below the frontier. Second, an outward
shift may occur only to DMU at the frontier,
when the average efficiency decreases, which
may indicate technological or process innovation which increases the gap efficiency between
the leader and the rest of the industry. Thus,
internally this also meant decrease in relative
efficiency across the board to players below the
frontier (Mazumdar dan Rajeev, 2009).
The third column in Table 7 shows technological change of greater than one means that
there may be technological applications which
increase efficiency significantly, relative to the
previous year. Data showed that the Indonesian
pharmaceutical industry only experienced one
increase (progress) during the 2006-2011 periods, which is during 2009 with an increase of
Technological Change of 43%. This increase
in Technology may occur when new entrants
utilize superior technology or existing players
invest in a new technology which influences the
frontier and existing DMU below the frontier
(Mazumdar dan Rajeev, 2009). However, more
accurate explanation would be that the global
financial crisis in 2009 forced existing players
to upgrade their technology to cope with the
fluctuation of raw material prices due to currency fluctuations, by using less input to produce
more or the same amount of output.
The fourth column of Table 7 shows Efficiency Change which explains the changes in
efficiency between periods. Efficiency change
of greater than one showed an increase in efficiency from the previous year, while a value
of less than one showed a decrease in efficiency
from the previous year. During 2007 and 2009,
Indonesian pharmaceutical industry experienced decrease in average efficiency of 9% and
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23% when compared to 2006 and 2008, respectively. While during year 2008, 2010 and 2011,
there were increasing in the average efficiency
from earlier year, of 16%, 4.1% and 13.5% respectively.
Compared to the technological change, the
level of efficiency change tends to be more
fluctuative, even though the overall technological change was decreasing. This showed
that companies in the Indonesian pharmaceutical industry could increase their efficiency
without increasing application of technologies.
However, in overall the Total Factor Productivity (TFP) shown in the fifth column of Table
7 showed TFP decreased during the decrease
in Technological change and increased during
the application of newer technology. In other
words, TFP are more affected by technological changes rather than changes in internal efficiency. This finding may be contradictive to the
findings of Gonzales and Gascon (2004) studying the Spanish pharmaceutical industry along
with Mazumdar and Rajeev (2009) studying the
Indian pharmaceutical companies. Both study
found that TFP was affected more by changes
in the internal efficiency rather than technological changes. This difference showed that
the Indonesian pharmaceutical companies can
enjoy the benefits of technological innovations
in producing pharmaceutical products due to an
increase of efficiency.
In summary, the findings in this paper suggest
the importance of using a more accurate measure based on an input-output framework, such
as DEA, to evaluate firm efficiency instead of
relying on efficiency measures based on financial ratios. Different with previous studies, such
as Pannu et al. (2011), this paper does not find
significant difference between the efficiency of
foreign owned and locally owned pharmaceutical companies. One possible explanation about
this finding is the stricter regulation in the Indonesian pharmaceutical industry which hinders
the benefits of economies of scale and transfer
of technology. However, whether and how regulation may impact firm efficiency in different
countries, especially in the pharmaceutical industry, may need further research.
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Conclusion
This study concludes that the five topmost
efficient pharmaceutical companies in Indonesia are Tempo Scan Pasific Tbk, Taisho Pharmaceutical Indonesia Tbk, Millennium Pharmacon
International Tbk, Indofarma Tbk and Pyridam
Farma Tbk. Calculating efficiency using DEA
are more accurate than using efficiency financial ratios due to its capability in capturing
all aspect of company activities rather than a
partial view as used in the ratios. It is also in
line with research Xu and Wang (2009) which
states that, in the proposed prediction scheme,
the efficiency of corporation is more efficient
obtained through DEA rather than using efficiency financial ratio analysis.
Further, this study finds no evidence that
foreign owned pharmaceutical companies are
more efficient than local companies. Differences in efficiency are more due to selection of
market and product segment rather than ownership. Companies with greater sales contribution
of over the counter medicine are generally more
efficient than companies which focus on prescribed medicines. This study also showed that
the Total Factor Productivity (TFP) of Indonesian pharmaceutical industry is more influenced
by technological changes than changes in internal efficiency. This finding is in opposite to the
findings in India and Spain in which changes in
TFP is influenced more by changes in internal
efficiency rather than technological changes.
The findings of this study must be seen in the
context of several limitations. This study only
used pharmaceutical companies listed in the Indonesian stock exchange which only accounts
to 9.24% of the total pharmaceutical companies
operating in Indonesia. This study measures
difference of efficiency based on ownership,
but not based on productivity due to insufficient
data on production volume and the utilization
of machinery and manpower by each company. Even so, this study employed a valid and
robust research method which have been tried
and tested in previous researches, therefore the
results are accountable.
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